Ingmar Bruns insider trades

Open-market stock purchases and sales by Ingmar Bruns, Chief Medical Officer at Zentalis Pharmaceuticals, Inc, from SEC Form 4 filings since Nov 17, 2021.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +62%.

Recent trades

DateStockTradeValue
Feb 9, 2026ZNTL Zentalis Pharmaceuticals, IncSold$802
Feb 6, 2026ZNTL Zentalis Pharmaceuticals, IncSold$7.2K
Jan 8, 2026ZNTL Zentalis Pharmaceuticals, IncBought (not open market)—

Companies traded

  • ZNTL Zentalis Pharmaceuticals, Inc: 1 buy, 2 sales, last Feb 9, 2026
  • TRIL Trillium Therapeutics Inc: other filings, last Nov 17, 2021

Get free alerts when Ingmar Bruns files a new trade →